Literature DB >> 2044564

Torsades de pointes after intracoronary papaverine.

M Vrolix1, J Piessens, H De Geest.   

Abstract

Coronary blood flow velocity and coronary flow reserve can be assessed in humans using a coronary Doppler catheter and the vasodilator papaverine. Although it is a safe, elegant and reproducible technique, serious complications can occur. Coronary flow reserve assessment in a 49-year-old man with a critical stenosis in the proximal part of the circumflex artery was complicated by a papaverine-induced ventricular arrhythmia. Several features of the present case report support papaverine-induced disturbances of the repolarization phase as the pathophysiological mechanism: a 'torsade de pointes' pattern of the tachycardia, the lengthening of the QT-interval, the appearance of a new U-wave and the presence of additional risk factors (hypokalaemia and alcalosis). Patients presenting additional risk factors for this complication should be excluded from coronary flow reserve assessment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044564     DOI: 10.1093/oxfordjournals.eurheartj.a059880

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Intracoronary papaverine and complete atrioventricular block.

Authors:  D A Chauhan; P A Mullins; S T Thuraisingham; P M Schofield
Journal:  BMJ       Date:  1992-10-10

Review 2.  Perioperative torsade de pointes: a systematic review of published case reports.

Authors:  Joshua Johnston; Swatilika Pal; Peter Nagele
Journal:  Anesth Analg       Date:  2013-06-06       Impact factor: 5.108

3.  Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.

Authors:  Yoshitaka Okabe; Kanichi Otowa; Yasuhito Mitamura; Hisayoshi Murai; Soichiro Usui; Shuichi Kaneko; Masayuki Takamura
Journal:  Heart Vessels       Date:  2018-04-30       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.